

# Improving Patient Care through the Use of Evidence-based, Interdisciplinary Transfusion Protocols

---

## References

1. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. *Arch Surg*. 1997; 132:620-4; discussion 624-5.
2. Claridge JA, Sawyer RG, Schulman AM et al. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. *Am Surg*. 2002; 68:566-72.
3. Malone DL, Dunne J, Tracy JK et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. *J Trauma*. 2003; 54:898-905; discussion 905-7.
4. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? *Chest*. 1995; 108:767-71.
5. Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. *JAMA*. 1991; 265:86-90.
6. Pell LJ, Martin BS, Shirk MB. Epoetin alfa protocol and multidisciplinary blood-conservation program for critically ill patients. *Am J Health-Syst Pharm*. 2005; 62:400-5.
7. Riley W, Schwei M, McCullough J. The United States' potential blood donor pool: estimating the prevalence of donor-exclusion factors on the pool of potential donors. *Transfusion*. 2007; 47:1180-8.
8. AuBuchon JP. Meeting transfusion safety expectations. *Ann Intern Med*. 2005; 143:537-8.
9. *Serious Hazards of Transfusion Annual Report 2005*. <http://www.shotuk.org/Summary%202005.pdf> (accessed 2007 Nov 9).
10. Blajchman MA, Beckers EA, Dickmeiss E et al. Bacterial detection of platelets: current problems and possible resolutions. *Transfus Med Rev*. 2005; 19:259-72.
11. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. *Blood*. 2005; 105:2266-73.

12. Moskowitz DM, Klein JJ, Shander A et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center. *Ann Thorac Surg.* 2004; 77:626-34.
13. Procrit package insert. Amgen, Inc; Thousand Oaks, CA: November 8, 2007.
14. Aranesp package insert. Amgen, Inc; Thousand Oaks, CA: November 8, 2007.
15. An open-label, randomized, parallel group study to confirm the safety and efficacy of PROCRT<sup>®</sup> (epoetin alfa) administered perioperatively versus the standard of care in blood conservation in subjects undergoing major elective spinal surgery.  
[http://download.veritasmedicine.com/PDF/CR004621\\_CSR.pdf](http://download.veritasmedicine.com/PDF/CR004621_CSR.pdf) (accessed 2007 Nov 14).
16. U.S. Food and Drug Administration. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]  
<http://www.fda.gov/cder/drug/infoSheets/HCP/RHE200711HCP.htm> (accessed 2007 Dec 10).
17. Henry DA, Carless P, Moxey A et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev.* 2007; (4):CD001886.
18. Henry DA, Moxey AJ, Carless PA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev.* 2001; (1):CD001886.
19. Mannucci PM, Levi M. Prevention and treatment of major blood loss. *N Engl J Med.* 2007; 356:2301-11.
20. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 Suppl):188S-203S.
21. Norfolk DR, Ancliffe PJ, Contreras M et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. *Br J Haematol.* 1998; 101:609-17.
22. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. *Clin Chest Med.* 2003; 24:607-22.
23. Hoffman M, Monroe DM 3<sup>rd</sup>. A cell-based model of hemostasis. *Thromb Haemost.* 2001; 85:958-65.

24. Sachs B, Delacy D, Green J et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. *Spine*. 2007; 32:2285-93.  
<http://www.spinejournal.com/pt/re/spine/abstract.00007632-200710010-00002.htm;jsessionid=H2ThtZdq0WT8p24yrnCjD6jVsHTxsympKmLySn0r0jl7hT81DTyS!1821113646!181195629!8091!-1> (accessed 2007 Nov 10).
25. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*. 1999; 340:409-17.
26. Dutton RP. Goals of therapy in common bleeding emergencies. *Pharmacotherapy*. 2007; 27(9 Pt 2):85S-92S.
27. Sauaia A, Moore FA, Moor EE et al. Epidemiology of trauma deaths: a reassessment. *J Trauma*. 1995; 38:185-93.
28. Shander A, Goodnough LT. Update on transfusion medicine. *Pharmacotherapy*. 2007; 27(9 Pt 2):57S-68S.
29. Dutton RP, McCunn M, Hyder M et al. Factor VIIa for correction of traumatic coagulopathy. *J Trauma*. 2004; 57:709-18; discussion 718-9.
30. Boffard KD, Riou B, Warrant B et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. *J Trauma*. 2005; 59:8-18.
31. O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA*. 2006; 295:293-8.
32. NovoSeven package insert. Princeton, NJ: Novo Nordisk; October 13, 2006.
33. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004; 126(3 Suppl):287S-310S.
34. Steiner T, Kaste M, Forsting M et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative

- Writing Committee and the Writing Committee for the EUSI Executive Committee. *Cerebrovasc Dis.* 2006; 22:294-316.
35. Franke CL, de Jonge J, van Swieten JC et al. Intracerebral hematomas during anticoagulant treatment. *Stroke.* 1990; 21:726-30.
  36. Sjoblom L, Hardemark HG, Lindgren A et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. *Stroke.* 2001; 32:2567-74.
  37. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. *Stroke.* 2006; 37:256-62.
  38. Fiore LD, Scola MA, Cantillon CE et al. Anaphylactoid reactions to vitamin K. *Thromb Thrombolysis.* 2001; 11:175-83.
  39. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 Suppl):204S-33S.
  40. Sorensen B, Johansen P, Nielsen GL et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. *Blood Coagul Fibrinolysis.* 2003; 14:469-77.
  41. Lin J, Hanigan WC, Tarantino M et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. *J Neurosurg.* 2003; 98:737-40.
  42. Guidelines on oral anticoagulation: third edition. *Br J Haematol.* 1998; 101:374-87.
  43. Hanley JP. Warfarin reversal. *J Clin Pathol.* 2004; 57:1132-9.
  44. Baker RI, Coughlin PB, Gallus AS et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. *Med J Aust.* 2004; 181:492-7.
  45. Mannucci PM. Hemostatic drugs. *N Engl J Med.* 1998; 339:245-53.
  46. Stramer SL. Current risks of transfusion-transmitted agents: a review. *Arch Pathol Lab Med.* 2007 131:702-7.

47. Bihl F, Castelli D, Marincola F et al. Transfusion-transmitted infections. *J Transl Med.* 2007; 5:25.
48. Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. *Thromb Haemost.* 1997; 77:477-80.
49. Boulis NM, Bobek MP, Schmaier A et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. *Neurosurgery.* 1999; 45:1113-8.